探讨介入治疗糖尿病合并下肢动脉阻塞性病变的可行性及疗效。

我院32例糖尿病合并下肢动脉阻塞性病变的患者，经非顺应性球囊导管行经皮腔内血管成形术（PTA）进行介入开通治疗。

32例患者术后6、12和24个月的初次通畅率分别为（83.6±5.1）%、（56.4±6.8）%、（48.3±8.2）%，二次通畅率为（89.3±4.1）%、（78.6±5.7）%、（64.8±7.3）%，肢体保存率为（89.3±5.1）%、（85.7±4.8）%、（82.2±5.5）%。均随随防时间的延长而降低。

经皮血管再通治疗糖尿病合并下肢动脉阻塞性病变创伤小，并发症及死亡率低，已成为一种替代外科血管旁路移植手术治疗慢性下肢缺血的首选方法。

To investigate the feasibility and efficacy of interventional therapy for diabetic patients with lower extremity arterial occlusive disease.

to analyze the clinical data of 32 patients with lower limb ischemia treated by interventional therapy(percutaneous transluminal angioplasty, PTA) in our hospital.

The primary patency rate of 6,12,24 months was(83.6±5.1)%, (56.4±6.8)%, (48.3±8.2)%; secondary patency rate of 6, 12, 24 months was (89.3±4.1)%, (78.6±5.7)%, (64.8±7.3)%. The limb survival rate of 6,12,24 months was(89.3±3.2)%, (85.7±4.8)%, (82.2±5.5)% respectively, all decreased with follow-up time.

Percutaneous revascularization is a new method to treat chronic lower limb ischemia with the advantages of less trauma, complications and low mortality.